Status:
COMPLETED
Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis
Lead Sponsor:
Laboratoires Thea
Conditions:
Acute Adenoviral Keratoconjunctivitis
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The study objective is to evaluate the efficacy and the safety of GV 550 in comparison to placebo in patients with acute adenoviral keratoconjuncivitis.
Eligibility Criteria
Inclusion
- Written informed consent
- Male or female aged from 18 to 80 years old
- Acute adenoviral keratoconjunctivitis
Exclusion
- Active ocular allergy
- Ocular herpès disease
- History of bacterial conjunctivitis / blepharoconjunctivitis within the last month before the inclusion visit
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01156025
Start Date
March 1 2009
End Date
June 1 2010
Last Update
July 2 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Director
Clermont-Ferrand, France, 63000